litlas
Log inCreate account

Martin Kolb

Active 2001–2025

175
Papers
28,273
Citations
81
h-index
164
i10-index

Citations

Citations per year for Martin Kolb1993: 1 citations2001: 6 citations2002: 19 citations2003: 51 citations2004: 51 citations2005: 71 citations2006: 67 citations2007: 91 citations2008: 75 citations2009: 113 citations2010: 109 citations2011: 100 citations2012: 101 citations2013: 102 citations2014: 115 citations2015: 162 citations2016: 200 citations2017: 265 citations2018: 263 citations2019: 1,012 citations2020: 1,299 citations2021: 1,433 citations2022: 1,231 citations2023: 1,010 citations2024: 1,684 citations2025: 743 citations2026: 19 citations1994–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,594 citing papers, 22.7% of this breakdownChina: 1,312 citing papers, 11.5% of this breakdownUnited Kingdom: 850 citing papers, 7.4% of this breakdownGermany: 736 citing papers, 6.4% of this breakdownItaly: 602 citing papers, 5.3% of this breakdownCanada: 578 citing papers, 5.1% of this breakdownJapan: 536 citing papers, 4.7% of this breakdownFrance: 508 citing papers, 4.5% of this breakdownAustralia: 350 citing papers, 3.1% of this breakdownNetherlands: 296 citing papers, 2.6% of this breakdownSpain: 287 citing papers, 2.5% of this breakdownSouth Korea: 243 citing papers, 2.1% of this breakdown
0%22.7%Other 22.1%

Institutions

Fields

  • Medicine79.8%
  • Biochemistry, Genetics and Molecular Biology12%
  • Immunology and Microbiology3.7%
  • Engineering0.8%
  • Neuroscience0.6%
  • Environmental Science0.5%
  • Other2.6%

Topics

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis19.8%
  • Systemic Sclerosis and Related Diseases4.3%
  • Chronic Obstructive Pulmonary Disease (COPD) Research3.7%
  • Pulmonary Hypertension Research and Treatments3%
  • Sarcoidosis and Beryllium Toxicity Research2.9%
  • Neonatal Respiratory Health Research2.7%
  • Other63.6%

Coauthors

All papers

Open in search
  1. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

    Authors: Luca Richeldi, Roland M. du Bois, Ganesh Raghu, Arata Azuma, Kevin M. Brown, Ulrich Costabel, Vincent Cottin, Kevin R. Flaherty, David M. Hansell, Yoshikazu Inoue, Dong Soon Kim, Martin Kolb, Andrew G. Nicholson, Paul W. Noble, Moisés Selman, Hiroyuki Taniguchi, Michèle Brun, Florence Le Maulf, M Girard, Susanne Stowasser, Rozsa Schlenker‐Herceg, Bernd Disse, Harold R. Collard - New England Journal of Medicine 2014 cited by 4,611

  2. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

    Authors: Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Simon Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser, Carl Coeck, Emmanuelle Clerisme-Beaty, Bernd Rosenstock, Manuel Quaresma, Thomas Haeufel, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown - New England Journal of Medicine 2019 cited by 2,346

  3. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

    Authors: Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin Hostettler, Susanne Stowasser, Martin Kolb - European Respiratory Journal 2015 cited by 986

  4. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

    Authors: Harold R. Collard, Christopher J. Ryerson, Tamera J. Corte, Gísli Jenkins, Yasuhiro Kondoh, David J. Lederer, Joyce Lee, Toby M. Maher, Athol U. Wells, Κατερίνα Αντωνίου, Jürgen Behr, Kevin M. Brown, Vincent Cottin, Kevin R. Flaherty, Junya Fukuoka, David M. Hansell, Takeshi Johkoh, Naftali Kaminski, Dong Soon Kim, Martin Kolb, David A. Lynch, Jeffrey L. Myers, Ganesh Raghu, Luca Richeldi, Hiroyuki Taniguchi, Fernando J. Martínez - American Journal of Respiratory and Critical Care Medicine 2016 cited by 1,444

  5. Idiopathic pulmonary fibrosis: state of the art for 2023

    Authors: Anna J. Podolanczuk, Carey C. Thomson, Martine Rémy‐Jardin, Luca Richeldi, Fernando J. Martínez, Martin Kolb, Ganesh Raghu - European Respiratory Journal 2023 cited by 320

  6. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

    Authors: Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim Wuyts, Susanne Stowasser, Manuel Quaresma, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Martin Kolb, Shuichi Abe, Myriam Aburto, Orlando Acosta, Charles Andrews, Danielle Antin‐Ozerkis, German Arce, Manuel Arias, С. Н. Авдеев, Adam Barczyk, Rebecca Bascom, Е. Д. Баздырев, Paul Beirne, Elizabeth A. Belloli, Miguel Bergna, Emmanuel Bergot, Nitin Bhatt, Stefan Blaas, Benjamin Bondue, Francesco Bonella, E. James Britt, Ketan Buch, John R. Burk, Hourong Cai, André M. Cantin, D.M. Castillo Villegas, Agustina Díaz Cazaux, Stefania Cerri, Said Chaaban, Nazia Chaudhuri, Vincent Cottin, Bruno Crestani, Gerard J. Criner, Caroline Dahlqvist, Sonye K. Danoff, J. Dematte D'Amico, Daniel F. Dilling, Paulo Eduardo Elias, Neil Ettinger, Jeremy Falk, Evans R. Fernández Pérez, A. Gamez-Dubuis, G. Giessel, Alex H. Gifford, Marilyn K. Glassberg, Craig S. Glazer, Jeffrey A. Golden, Luis Gómez Carrera, Julien Guiot, Robert W. Hallowell, Hiroki Hayashi, J. Hetzel, Nik Hirani, L. Homik, Benjamin Hope-Gill, David Hotchkin, Kazuya Ichikado, M. M. Ilkovich, Yoshikazu Inoue, Shinyu Izumi, Ewa Jassem, Leonie Jones, S. Jouneau, Robert J. Kaner, Jian Kang, Tsuyoshi Kawamura, Romain Kessler, Y. Kim, Kazuma Kishi, Hideya Kitamura, Martin Kolb, Yasuhiro Kondoh, Chiyoko Kono, Dirk Koschel, Michael Kreuter, Tejaswini Kulkarni, Jan Kuś, F. Lebargy, Antonio León Jiménez, Qun Luo, Yolanda Mageto, Toby M. Maher, Shigeki Makino, S. Marchand‐Adam, Charles‐Hugo Marquette, Raquel Martínez, Martin Ulises Gutierrez Martinez and 68 more - The Lancet Respiratory Medicine 2020 cited by 559

  7. Progressive pulmonary fibrosis: an expert group consensus statement

    Authors: Sujeet Rajan, Vincent Cottin, Raja Dhar, Sonye K. Danoff, Kevin R. Flaherty, Kevin K. Brown, Anant Mohan, Elizabeth Renzoni, Murali Mohan, Zarir Udwadia, Padmanabha Shenoy, David C. Currow, Anand Devraj, Bhavin Jankharia, Ritu Kulshrestha, Steve Jones, Claudia Ravaglia, Sílvia Quadrelli, Rajam K Iyer, Sahajal Dhooria, Martin Kolb, Athol U. Wells - European Respiratory Journal 2022 cited by 233

  8. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

    Authors: Antje Moeller, Kjetil Ask, David Warburton, Jack Gauldie, Martin Kolb - The International Journal of Biochemistry & Cell Biology 2007 cited by 994

  9. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

    Authors: Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F. Dellaripa, Bibek Gooptu, Robert Vassallo, Gerard Cox, Kevin R. Flaherty, Huzaifa Adamali, Michael Gibbons, Lauren Troy, Ian Forrest, Joseph A. Lasky, Lisa Spencer, Jeffrey A. Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A. Perrella, David A. Lynch, Daniel C. Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary J. Goldberg, Iván O. Rosas, Shana Haynes-Harp, F. Poli, Coimbatore Sree Vidya, Rebecca R. Baron, Timothy Clouser, Tracy J. Doyle, Anthony H. Maeda, Kristin B. Highland, Jemima F. Albayda, Sarah E. Collins, Karthik Suresh, John M. Davis, Andrew H. Limper, Isabel Amigues, Kristina Eliopoulos, Jeffery J. Swigris, Stephen M. Humphries, John Huntwork, Chris Glynn, Steve Duncan, Maria I. Danila, Marilyn K. Glassberg, Elana M. Oberstein, Elizabeth A. Belloli, Linda Briggs, Vivek Nagaraja, Linda Cholewa, Donna DiFranco, Edward Green, Christie Liffick, Tanvi Naik, Genevieve Montas, Dorota Lebiedz‐Odrobina, Reba Bissell, Mark H. Wener, Lisa Lancaster, Leslie J. Crawford, Karmela K Chan, Robert J. Kaner, Alicia Morris, Xiaoping Wu, Nader Khalidi, Christopher J. Ryerson, Alyson W. Wong, Charlene D. Fell, Sharon LeClercq, Mark Hyman, Shane Shapera, Shikha Mittoo, Shireen Shaffu, Karl Gaffney, Andrew M. Wilson, Shaney Barratt, Harsha Gunawardena, Rachel K. Hoyles, Joel David, Namrata Kewalramani, Toby M. Maher, Philip L. Molyneaux, Maria Kokosi, Matthew Cates, Mandizha Mandizha, Abdul Ashish, Gladstone Chelliah, Helen Parfrey, Muhunthan Thillai, Josephine Vila, Sophie Fletcher, Paul Beirne, C Favager, Jo Brown, Julie Dawson and 7 more - The Lancet Respiratory Medicine 2022 cited by 208

  10. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis

    Authors: Gísli Jenkins, Bethany B. Moore, Rachel C. Chambers, Oliver Eickelberg, Mélanie Königshoff, Martin Kolb, Geoffrey J. Laurent, Carmel B. Nanthakumar, Mitchell A. Olman, Annie Pardo, Moisés Selman, Dean Sheppard, Patricia J. Sime, Andrew M. Tager, Amanda L. Tatler, Victor J. Thannickal, Eric S. White - American Journal of Respiratory Cell and Molecular Biology 2017 cited by 431

  11. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

    Authors: David J. Lederer, Scott C. Bell, Richard D. Branson, James D. Chalmers, Rachel Marshall, David M. Maslove, David E. Ost, Naresh M. Punjabi, Michael Schätz, Alan R Smyth, Paul W. Stewart, Samy Suissa, Alex A. Adjei, Cezmi A. Akdiş, Élie Azoulay, Jan Bakker, Zuhair K. Ballas, Philip G. Bardin, Esther Barreiro, Rinaldo Bellomo, Jonathan A. Bernstein, Vito Brusasco, Timothy G. Buchman, Sudhansu Chokroverty, Nancy A. Collop, James D. Crapo, Dominic A. Fitzgerald, Lauren Hale, Nicholas Hart, Felix Herth, Theodore J. Iwashyna, Gísli Jenkins, Martin Kolb, Guy B. Marks, Peter J. Mazzone, J. Randall Moorman, Thomas M. Murphy, Terry L. Noah, Paul N. Reynolds, Dieter Riemann, Richard Russell, Aziz Sheikh, Giovanni Sotgiu, Erik R. Swenson, Rhonda D. Szczesniak, Ronald Szymusiak, Jean–Louis Teboul, Jean‐Louis Vincent - Annals of the American Thoracic Society 2018 cited by 722

  12. The importance of interventional timing in the bleomycin model of pulmonary fibrosis

    Authors: Philipp Kolb, Chandak Upagupta, Megan Vierhout, Ehab Ayaub, Pierre Simon Bellaye, Jack Gauldie, Chiko Shimbori, Mark D. Inman, Kjetil Ask, Martin Kolb - European Respiratory Journal 2020 cited by 199

  13. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

    Authors: Nathan Hambly, Mohammed A. Farooqi, Anna Dvorkin‐Gheva, Kathryn Donohoe, Kristopher Garlick, Ciaran Scallan, Sy Giin Chong, S. Macisaac, Deborah Assayag, Kerri A. Johannson, Charlene D. Fell, Veronica Marcoux, H. Manganas, Julie Morisset, Alessia Comes, Jolene H. Fisher, Shane Shapera, Andrea S. Gershon, Teresa To, Alyson W. Wong, Mohsen Sadatsafavi, Pierce G. Wilcox, Andrew J. Halayko, Nasreen Khalil, Gerard Cox, Luca Richeldi, Christopher J. Ryerson, Martin Kolb - European Respiratory Journal 2022 cited by 185

  14. Matrix abnormalities in pulmonary fibrosis

    Authors: Chandak Upagupta, Chiko Shimbori, Rahmah Alsilmi, Martin Kolb - European Respiratory Review 2018 cited by 277

  15. Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

    Authors: Ganesh Raghu, Sydney B. Montesi, Richard M. Silver, Tanzib Hossain, Madalina Macrea, Derrick Herman, Hayley Barnes, Ayodeji Adegunsoye, Arata Azuma, Leland W.K. Chung, Gregory C. Gardner, Kristin B. Highland, Marie Hudson, Robert J. Kaner, Martin Kolb, Mary Beth Scholand, Virginia Steen, Carey C. Thomson, Elizabeth R. Volkmann, Fredrick M. Wigley, Dee Burlile, Karen Kemper, Shandra L. Knight, Marya Ghazipura - American Journal of Respiratory and Critical Care Medicine 2023 cited by 160

  16. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

    Authors: Lutz Wollin, Jörg H. W. Distler, Elizabeth F. Redente, David W. H. Riches, Susanne Stowasser, Rozsa Schlenker‐Herceg, Toby M. Maher, Martin Kolb - European Respiratory Journal 2019 cited by 296

  17. What's in a name? That which we call IPF, by any other name would act the same

    Authors: Athol U. Wells, Kevin K. Brown, Kevin R. Flaherty, Martin Kolb, Victor J. Thannickal - European Respiratory Journal 2018 cited by 352

  18. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis

    Authors: Martin Kolb, Peter J. Margetts, Daniel C. Anthony, Fernando J. Pitossi, Jack Gauldie - Journal of Clinical Investigation 2001 cited by 741

  19. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice

    Authors: Tina Bormann, Regina Maus, Jennifer Stolper, Meritxell Tort Tarrés, Christina Brandenberger, Dirk Wedekind, Danny Jonigk, Tobias Welte, Jack Gauldie, Martin Kolb, Ulrich A. Maus - Respiratory Research 2022 cited by 92

  20. The natural history of progressive fibrosing interstitial lung diseases

    Authors: Martin Kolb, Martina Vašáková - Respiratory Research 2019 cited by 266

  21. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

    Authors: Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Luca Richeldi, Simon Walsh, Martin Kolb, Dirk Koschel, Teng Moua, Susanne Stowasser, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown - European Respiratory Journal 2021 cited by 115

  22. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

    Authors: Martin Kolb, Bruno Crestani, Toby M. Maher - European Respiratory Review 2023 cited by 74

  23. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner

    Authors: Tamara Krneta, Amy Gillgrass, Sophie M. Poznanski, Marianne V. Chew, Amanda J. Lee, Martin Kolb, Ali A. Ashkar - Journal of Leukocyte Biology 2016 cited by 112

  24. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial

    Authors: Eric L. Matteson, Martin Aringer, Gerd R Burmester, Heiko Mueller, Lizette Moros, Martin Kolb - Clinical Rheumatology 2023 cited by 76